Section 1e: Version 3 (V3)
Section 2: Clinical and Administrative Domains

HL7 Version 3 Domain Analysis Model: Allergy and Intolerance, Release 1

DESCRIPTION

The Allergy and Intolerance Domain Analysis Model is broad, and is intended to unify a number of international models designed to deal with the documentation and interoperability of allergy and intolerance conditions.  The use cases and models were developed with several goals in mind.  The first goal was to provide the reader examples of the following concepts:

  • Documentation of a newly observed vs. reported allergy or intolerance
  • To establish that an allergy and intolerance should be treated as an adverse reaction until clearly differentiated (by test, or by clinical opinion)
  • To delineate the difference between severity and criticality and how to apply these concepts to an adverse reaction vs. a condition
  • To demonstrate the creation and maintenance of an allergy and intolerance list, as well as identify how to update a list after misattribution, or ensure that some statement of assessment is included on the list (no known allergies, unable to determine), and how to address an allergy entered in error. 
  • To demonstrate the reconciliation of two different allergy and intolerance lists.

ALTERNATIVE NAMES

HL7 Version 3 Domain Analysis Model: Allergy and Intolerance, Release 1 may also go by the following names or acronyms:

"V3 DAM: Allergies and Intolerances, R1"

TARGETS

  • Clinical and Public Health Laboratories
  • Immunization Registries
  • Quality Reporting Agencies
  • Standards Development Organizations (SDOs)
  • Payors
  • Pharmaceutical Vendors
  • EHR, PHR Vendors
  • Health Care IT Vendors
  • Clinical Decision Support Systems Vendors
  • Lab Vendors
  • HIS Vendors
  • FNMS Vendors
  • Emergency Services Providers
  • Local and State Departments of Health
  • Medical Imaging Service Providers
  • Healthcare Institutions (hospitals, long term care, home care, mental health)

BENEFITS

  • Creates a standard model for the documentation and interoperability of adverse reactions
  • Allows for the creation of value sets to standardize the substances and products associated with adverse reactions.
  • Supports other HL7 and US Realm projects that have noted the lack of allergy and intolerance standards.
  • Provides a clear set of use cases to support the C-CDA, FHIR, CDS and vMR
  • Provides an integrated view of concepts related to adverse reactions to substances including drugs, food, environmental allergens and devices
  • Represents the synthesis of a number of international models in an area where currently no universal standard exists for allergy and intolerances

IMPLEMENTATIONS/CASE STUDIES

  • HL7 creating RMIM/DMIMs
  • Sponsor – Academy of Nutrition and Dietetics

RELATED DOCUMENTS

HL7 Version 3 Domain Analysis Model: Allergy and Intolerance, Release 1

(Download) (1.23 MB)

TOPICS

  • Care Provision
  • Decision Support
  • Patient Care
  • Pharmacy
  • Terminology

BALLOT TYPE

  • DSTU

STATUS DATE

2014-03-25

RESPONSIBLE WORK GROUP

Patient Care

PRODUCT TYPE

  • Domain Analysis Model

STAKEHOLDERS

  • Clinical and Public Health Laboratories
  • Clinical Decision Support Systems Vendors
  • EHR, PHR Vendors
  • Emergency Services Providers
  • Health Care IT Vendors
  • Healthcare Institutions
  • HIS Vendors
  • Immunization Registries
  • Lab Vendors
  • Local and State Departments of Health
  • Medical Imaging Service Providers
  • Payors
  • Pharmaceutical Vendors
  • Quality Reporting Agencies
  • Standards Development Organizations (SDOs)

FAMILY

  • V3

CURRENT STATE

  • Retired

REALM

  • Universal